Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity

Cancer Discovery

Volumn 7, Issue 7, 2017, Pages 750-765

  Patnaik, Akash ^a,b   Swanson, Kenneth D ^a   Csizmadia, Eva ^c   Solanki, Aniruddh ^d,e   Landon Brace, Natalie ^d,e   Gehring, Marina P ^a,f   Helenius, Katja ^g   Olson, Brian M ^b   Pyzer, Athalia R ^a   Wang, Lily C ^h   Elemento, Olivier ^h   Novak, Jesse ^d   Thornley, Thomas B ^a   Asara, John M ^a   Montaser, Laleh ^a   Timmons, Joshua J ^a   Morgan, Todd M ⁱ   Wang, Yugang ⁱ   Levantini, Elena ^a,e,j   Clohessy, John G ^a   Kelly, Kathleen ^k   Pandolfi, Pier Paolo ^a   Rosenblatt, Jacalyn M ^a   Avigan, David E ^a   Ye, Huihui ^a   Karp, Jeffrey M ^d,e   Signoretti, Sabina ^d   Balk, Steven P ^a   Cantley, Lewis C ^h   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD STEM CELL INSTITUTE   (United States)

^f PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j CNR   (Italy)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CASPASE 3; CD4 ANTIGEN; CD8 ANTIGEN; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; ANILIDE; HETEROCYCLIC COMPOUND; HMGB1 PROTEIN, MOUSE; PLERIXAFOR; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, MOUSE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL MIGRATION ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; INNATE IMMUNITY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; NEUTROPHIL; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANILIDES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; HETEROCYCLIC COMPOUNDS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; MALE; MICE; NEUTROPHILS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; PYRIDINES; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85022060715     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0778     Document Type: Article

References (51)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860–7.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–8.
3. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263–6.
4. Jessy T. Immunity over inability: The spontaneous regression of cancer. J Nat Sci Biol Med 2011;2:43–9.
5. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298–308.
6. Nix NM, Braun K. Cabozantinib for the treatment of metastatic medullary thyroid carcinoma. J Adv Pract Oncol 2014;5:47–50.
7. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412–9.
8. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol 2016;34:3005–13.
9. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917–27.
10. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814–23.
11. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–28.
12. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239–43.
13. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013;45:747–55.
14. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725–30.
15. Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, et al. Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol Cancer Ther 2015;14:278–88.
16. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660–6.
17. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int 2010;60:497–505.
18. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol 2007;14:3–8.
19. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012;209:551–63.
20. Ding HS, Yang J, Gong FL, Yang J, Ding JW, Li S, et al. High mobility group [corrected] box 1 mediates neutrophil recruitment in myocar-dial ischemia-reperfusion injury through toll like receptor 4-related pathway. Gene 2012;509:149–53.
21. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324–31.
22. Fridman WH, Dieu-Nosjean MC, Pages F, Cremer I, Damotte D, Sautes-Fridman C, et al. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron 2013;6:117–22.
23. Savill J, Gregory C. Apoptotic PS to phagocyte TIM-4: eat me. Immunity 2007;27:830–2.
24. Palombo F, Focaccetti C, Barnaba V. Therapeutic implications of immunogenic cell death in human cancer. Front Immunol 2014;4:503.
25. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009;16:183–94.
26. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell 2009;16:173–4.
27. Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 2012;82:296–309.
28. Sionov RV, Fridlender ZG, Granot Z. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron 2015;8:125–58.
29. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother 2013;62:1745–56.
30. Zentay Z, Sharaf M, Qadir M, Drafta D, Davidson D. Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: role of neutrophil interleukin-8 release. Pediatr Res 1999;46:406–10.
31. Rahman MM, Alkhouri H, Tang F, Che W, Ge Q, Ammit AJ. Sphin-gosine 1-phosphate induces neutrophil chemoattractant IL-8: repression by steroids. PLoS One 2014;9:e92466.
32. Massena S, Christoffersson G, Vagesjo E, Seignez C, Gustafsson K, Binet F, et al. Identification and characterization of VEGF-A-respon-sive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood 2015;126:2016–26.
33. Yamada M, Kubo H, Kobayashi S, Ishizawa K, He M, Suzuki T, et al. The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury. Cell Mol Immunol 2011;8:305–14.
34. Zhou H, Wang Y, Wang W, Jia J, Li Y, Wang Q, et al. Generation of monoclonal antibodies against highly conserved antigens. PLoS One 2009;4:e6087.
35. Ilieva KM, Correa I, Josephs DH, Karagiannis P, Egbuniwe IU, Cafferkey MJ, et al. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014;13: 2769–83.
36. Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res 2014;2: 1044–50.
37. Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, et al. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 2016;46:409–19.
38. Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res 2014;2:351–60.
39. Manzini C, Vene R, Cossu I, Gualco M, Zupo S, Dono M, et al. Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. Oncotarget 2016;7:60858–71.
40. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015;7:279ra41.
41. Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 2014;515:134–7.
42. Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov 2016;6:630–49.
43. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007;26:1129–39.
44. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331–42.
45. Wong ET, Lok E, Gautam S, Swanson KD. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 2015;113:232–41.
46. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014;33: 641–55.
47. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810–7.
48. Quinn BA, Lee NA, Kegelman TP, Bhoopathi P, Emdad L, Das SK, et al. The quest for an effective treatment for an intractable cancer: established and novel therapies for pancreatic adenocarcinoma. Adv Cancer Res 2015;127:283–306.
49. Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ion-switch-ing, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc 2012;7:872–81.
50. Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng V, et al. Prostate epithelial Pten/TP53 loss leads to transformation of multi-potential progenitors and epithelial to mesenchymal transition. Am J Pathol 2011;179:422–35.
51. Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015;522:349–53.